Home > Boards > US Listed > Medical - Equipment > Pressure BioSciences Inc. (PBIO)

PBIO recent News: SOUTH EASTON, Mass., Oct. 01,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
jedijazz Member Profile
Member Level 
Followed By 1,143
Posts 149,410
Boards Moderated 51
Alias Born 12/07/09
160x600 placeholder
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/14/2019 5:21:10 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 11/6/2019 12:04:17 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/3/2019 6:31:21 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2019 11:03:38 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/21/2019 11:43:40 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/21/2019 11:42:55 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/21/2019 11:42:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/21/2019 11:41:09 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/21/2019 11:39:39 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/16/2019 9:49:17 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/15/2019 3:36:19 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/15/2019 3:31:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2019 7:56:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2019 7:54:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2019 7:51:57 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 4:51:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/1/2019 2:42:10 PM
Annual Report (10-k) Edgar (US Regulatory) - 4/16/2019 4:24:00 PM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 4/1/2019 5:07:03 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 3/20/2019 5:25:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/15/2019 5:28:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/31/2018 6:11:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/28/2018 5:24:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/26/2018 6:12:14 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2018 6:15:13 PM
jedijazz Member Level  Friday, 11/08/19 01:16:09 PM
Re: None
Post # of 11354 
PBIO recent News: SOUTH EASTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Pressure BioSciences, Inc. (PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the Company’s patented pressure cycling technology (“PCT”) platform was featured as an integral part of a new, innovative workflow for the analysis of proteins from cancer biopsy samples. This workflow was presented in a plenary session at the Annual Meeting of the International Gynecologic Cancer Society (“IGCS”) on September 21, 2019 in Rio de Janeiro, Brazil. The mission of the IGCS is to improve the care and outcomes for women with gynecologic cancer worldwide through education, training and public awareness.

According to Dr. Larry Maxwell, MD, gynecologic oncologist and Chair of OB-GYN at Inova Fairfax Hospital, “the conventional use of chemotherapy in ovarian cancer treatment is being rapidly replaced by biologic therapeutics that target the cancer (the “seed”) and also the micro-environment (the “soil”) in which it grows. Being able to collect small tissue specimens and characterize them across multiple genomic and proteomic platforms will enable us to markedly enhance our ability to develop companion diagnostics and prognostics as well as identify targets for future therapeutic strategies. Technology provided by Pressure BioSciences has become an essential requirement for our novel workflow in meeting our goals.”

https://www.marketwatch.com/press-release/networknewsbreaks---pressure-biosciences-incs-pbio-pct-platform-fills-integral-role-for-tumor-analyses-in-novel-workflow-presented-at-igcs-2019-10-01?mod=mw_quote_news


ALL comments are In My Own OPINION. Please Use Your Own DD for Stock Trading.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist